Common Contracts
20 similar Underwriting Agreement contracts by Lirum Therapeutics, Inc., Qilian International Holding Group LTD, RoyaLand Co Ltd., others
WELLCHANGE HOLDINGS COMPANY LIMITED UNDERWRITING AGREEMENTUnderwriting Agreement • August 19th, 2024 • Wellchange Holdings Co LTD • Services-prepackaged software • New York
GENELUX CORPORATION 6,875,000 Shares of Common Stock and Warrants to Purchase 6,875,000 Shares of Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • May 24th, 2024 • GENELUX Corp • Pharmaceutical preparations • New York
Genelux Corporation, a corporation organized and existing under the laws of the State of Delaware (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the several underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of (i) 6,875,000 shares (the “Firm Shares”) of its common stock, par value $0.001 per share (the “Common Stock”) and (ii) warrants (the “Firm Warrants,” together with the Firm Shares, the “Firm Securities”) to purchase up to 6,875,000 shares of Common Stock in the form set forth in Exhibit A hereto . The Company also proposes to issue and sell to the several Underwriters up to (i) an additional 1,031,250 shares (the “Additional Shares,”) of Common Stock and (ii) additional warrants to purchase an aggregate of 1,031,250 shares of Common Stock (the “Additional Warrants,” and collectively with the Firm Securities and Additional Shares, the “Securities”) at the option of the Underwriters as provided in Section 2
WELLCHANGE HOLDINGS COMPANY LIMITED UNDERWRITING AGREEMENTUnderwriting Agreement • March 27th, 2024 • Wellchange Holdings Co LTD • Services-prepackaged software • New York
UNDERWRITING AGREEMENT between LIRUM THERAPEUTICS, INC. and THINKEQUITY LLC as Representative of the Several Underwriters LIRUM THERAPEUTICS, INC. UNDERWRITING AGREEMENTUnderwriting Agreement • March 22nd, 2024 • Lirum Therapeutics, Inc. • Pharmaceutical preparations • New York
The undersigned, Lirum Therapeutics, Inc., a corporation formed under the laws of the State of Delaware (collectively with its affiliates, including, without limitation, all entities disclosed or described in the Registration Statement (as hereinafter defined) as being an affiliate of Lirum Therapeutics, Inc., the “Company”), hereby confirms its agreement (this “Agreement”) with ThinkEquity LLC (hereinafter referred to as “you” (including its correlatives) or the “Representative”) and with the other underwriters named on Schedule 1 hereto for which the Representative is acting as representative (the Representative and such other underwriters being collectively called the “Underwriters” or, individually, an “Underwriter”) as set forth below.
UNDERWRITING AGREEMENT between LIRUM THERAPEUTICS, INC. and THINKEQUITY LLC as Representative of the Several Underwriters LIRUM THERAPEUTICS, INC. UNDERWRITING AGREEMENTUnderwriting Agreement • March 11th, 2024 • Lirum Therapeutics, Inc. • Pharmaceutical preparations • New York
The undersigned, Lirum Therapeutics, Inc., a corporation formed under the laws of the State of Delaware (collectively with its affiliates, including, without limitation, all entities disclosed or described in the Registration Statement (as hereinafter defined) as being an affiliate of Lirum Therapeutics, Inc., the “Company”), hereby confirms its agreement (this “Agreement”) with ThinkEquity LLC (hereinafter referred to as “you” (including its correlatives) or the “Representative”) and with the other underwriters named on Schedule 1 hereto for which the Representative is acting as representative (the Representative and such other underwriters being collectively called the “Underwriters” or, individually, an “Underwriter”) as set forth below.
UNDERWRITING AGREEMENT between LIRUM THERAPEUTICS, INC. and THINKEQUITY LLC as Representative of the Several Underwriters LIRUM THERAPEUTICS, INC. UNDERWRITING AGREEMENTUnderwriting Agreement • February 2nd, 2024 • Lirum Therapeutics, Inc. • Pharmaceutical preparations • New York
The undersigned, Lirum Therapeutics, Inc., a corporation formed under the laws of the State of Delaware (collectively with its affiliates, including, without limitation, all entities disclosed or described in the Registration Statement (as hereinafter defined) as being an affiliate of Lirum Therapeutics, Inc., the “Company”), hereby confirms its agreement (this “Agreement”) with ThinkEquity LLC (hereinafter referred to as “you” (including its correlatives) or the “Representative”) and with the other underwriters named on Schedule 1 hereto for which the Representative is acting as representative (the Representative and such other underwriters being collectively called the “Underwriters” or, individually, an “Underwriter”) as set forth below.
UNDERWRITING AGREEMENTUnderwriting Agreement • November 30th, 2023 • RoyaLand Co Ltd. • Services-prepackaged software • New York
The undersigned, The RoyaLand Company Ltd., an exempted company incorporated in Bermuda with limited liability (the “Company”), hereby confirms its agreement (this “Agreement”) with Revere Securities, LLC together with its subsidiaries and affiliates (collectively “Revere,” hereinafter referred to as “you” or the “Representative”) and with the other underwriters named on Schedule 1 hereto for which the Representative is acting as representative (the Representative and such other underwriters being collectively called the “Underwriters” or, individually, an “Underwriter”) as follows:
UNDERWRITING AGREEMENTUnderwriting Agreement • November 8th, 2023 • WF International Ltd. • Construction - special trade contractors • New York
The undersigned, WF International Limited, an exempted company incorporated under the laws of the Cayman Islands (the “Company”), hereby confirms its agreement (this “Agreement”) with The Benchmark Company, LLC and Axiom Capital Management, Inc. (each, the “Representative”, and collectively, the “Representatives”) and with the other underwriters, if any, named on Schedule 1 hereto for which the Representatives are acting as Representative (the Representatives and such other underwriters being collectively called the “Underwriters” or, individually, an “Underwriter”) as follows:
UNDERWRITING AGREEMENTUnderwriting Agreement • June 30th, 2023 • RoyaLand Co Ltd. • Services-prepackaged software • New York
The undersigned, The RoyaLand Company Ltd., an exempted company incorporated in Bermuda with limited liability (the “Company”), hereby confirms its agreement (this “Agreement”) with Revere Securities, LLC together with its subsidiaries and affiliates (collectively “Revere,” hereinafter referred to as “you” or the “Representative”) and with the other underwriters named on Schedule 1 hereto for which the Representative is acting as representative (the Representative and such other underwriters being collectively called the “Underwriters” or, individually, an “Underwriter”) as follows:
UNDERWRITING AGREEMENTUnderwriting Agreement • November 4th, 2022 • Brera Holdings PLC • Services-amusement & recreation services • New York
The undersigned, Brera Holdings PLC, a public limited company incorporated in the Republic of Ireland (the “Company”), hereby confirms its agreement (this “Agreement”) with Revere Securities, LLC together with its subsidiaries and affiliates (collectively “Revere,” hereinafter referred to as “you” or the “Representative”) and with the other underwriters named on Schedule 1 hereto for which the Representative is acting as representative (the Representative and such other underwriters being collectively called the “Underwriters” or, individually, an “Underwriter”) as follows:
REGENCELL BIOSCIENCE HOLDINGS LIMITED UNDERWRITING AGREEMENTUnderwriting Agreement • July 20th, 2021 • Regencell Bioscience Holdings LTD • Medicinal chemicals & botanical products • New York
The undersigned, Regencell Bioscience Holdings Limited, a corporation incorporated under the laws of the Cayman Islands (the “Company”), hereby confirms its agreement (this “Agreement”) to issue and sell to the underwriter or underwriters, as the case may be, named in Schedule I hereto (each, an “Underwriter” and, collectively, the “Underwriters;”), for whom Maxim Group LLC is acting as representative (in such capacity, the “Representative”), (A) an aggregate of 2,300,000 ordinary shares (the “Firm Shares”) par value $0.00001 per share of the Company (“Ordinary Shares”) and (B) at the election of the Representative, (i) up to an additional 345,000 Ordinary Shares (the “Option Shares”, and together with the Firm Shares, the “Shares”). The offering and sale of the Shares contemplated by this Agreement is referred to herein as the “Offering”.
QILIAN INTERNATIONAL HOLDING GROUP LIMITED UNDERWRITING AGREEMENTUnderwriting Agreement • December 23rd, 2020 • Qilian International Holding Group LTD • Pharmaceutical preparations • New York
QILIAN INTERNATIONAL HOLDING GROUP LIMITED UNDERWRITING AGREEMENTUnderwriting Agreement • December 18th, 2020 • Qilian International Holding Group LTD • Pharmaceutical preparations • New York
UNDERWRITING AGREEMENT between VIRIOS THERAPEUTICS, INC. and THINKEQUITY A DIVISION OF FORDHAM FINANCIAL MANAGEMENT, INC. as Representative of the Several Underwriters VIRIOS THERAPEUTICS, INC. UNDERWRITING AGREEMENTUnderwriting Agreement • September 25th, 2020 • Virios Therapeutics, LLC • Pharmaceutical preparations • New York
The undersigned, Virios Therapeutics, Inc., a corporation formed under the laws of the State of Delaware (collectively with its subsidiaries and affiliates, including, without limitation, all entities disclosed or described in the Registration Statement (as hereinafter defined) as being subsidiaries or affiliates of Virios Therapeutics, Inc., the “Company”), hereby confirms its agreement (this “Agreement”) with ThinkEquity, a division of Fordham Financial Management, Inc., (hereinafter referred to as “you” (including its correlatives) or the “Representative”) and with the other underwriters named on Schedule 1 hereto for which the Representative is acting as representative (the Representative and such other underwriters being collectively called the “Underwriters” or, individually, an “Underwriter”) as follows:
QILIAN INTERNATIONAL HOLDING GROUP LIMITED UNDERWRITING AGREEMENTUnderwriting Agreement • November 27th, 2019 • Qilian International Holding Group LTD • Pharmaceutical preparations • New York
INTERPACE DIAGNOSTICS GROUP, INC. UNDERWRITING AGREEMENTUnderwriting Agreement • June 21st, 2017 • Interpace Diagnostics Group, Inc. • Surgical & medical instruments & apparatus • New York
Interpace Diagnostics Group, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell an aggregate of: (i) 9,900,000 shares (“Firm Shares”) of the Company’s common stock, $0.01 par value per share (“Shares”), (ii) warrants to purchase 12,500,000 Shares at an exercise price equal to $1.25 per share (“Base Warrants”), and (iii) warrants to purchase 2,600,000 Shares at an exercise price equal to $0.01 per share (“Pre-Funded Warrants”) to the several underwriters (such underwriters, for whom Maxim Group LLC (“Maxim” or the “Representative”) is acting as representative, the “Underwriters” and each an “Underwriter”). Each Firm Share shall be sold together with a Base Warrant to purchase one Share; or, alternatively, each Pre-Funded Warrant shall be sold, in lieu of a Share, together with a Base Warrant to purchase one Share. Such Base Warrants and Pre-Funded Warrants are hereinafter collectively called the “Firm Warrants,” a
AMERICAN DEPOSITARY SHARES, EACH REPRESENTING 40 ORDINARY SHARES, NIS 0.1 PAR VALUE THERAPIX BIOSCIENCES LTD. UNDERWRITING AGREEMENTUnderwriting Agreement • March 20th, 2017 • Therapix Biosciences Ltd. • Pharmaceutical preparations • New York
AMERICAN DEPOSITARY SHARES, EACH REPRESENTING 40 ORDINARY SHARES, NIS 0.1 PAR VALUE THERAPIX BIOSCIENCES LTD. UNDERWRITING AGREEMENTUnderwriting Agreement • March 3rd, 2017 • Therapix Biosciences Ltd. • Pharmaceutical preparations • New York
UNDERWRITING AGREEMENT between SURGIVISION, INC. and RODMAN & RENSHAW, LLC as RepresentativeUnderwriting Agreement • August 5th, 2010 • Surgivision Inc • Surgical & medical instruments & apparatus • New York
The undersigned, SurgiVision, Inc., a company formed under the laws of Delaware (the “Company”), hereby confirms its agreement with Rodman & Renshaw, LLC (hereinafter referred to as “you” (including its correlatives) or the “Representative”) and the other underwriters named on Schedule 1 hereto for which the Representative is acting as representative (the Representative and such other underwriters being collectively called the “Underwriters” or, individually, an “Underwriter”) as follows:
UNDERWRITING AGREEMENT between SURGIVISION, INC. and CANACCORD GENUITY INC. as RepresentativeUnderwriting Agreement • June 4th, 2010 • Surgivision Inc • Surgical & medical instruments & apparatus • New York
The undersigned, SurgiVision, Inc., a company formed under the laws of Delaware (the “Company”), hereby confirms its agreement with Canaccord Genuity Inc. (hereinafter referred to as “you” (including its correlatives) or the “Representative”) and the other underwriters named on Schedule 1 hereto for which the Representative is acting as representative (the Representative and such other underwriters being collectively called the “Underwriters” or, individually, an “Underwriter”) as follows:
